Early Detection of Esophageal Squamous Cancer With the Capsule Sponge Device

Esophageal squamous cell carcinoma accounts for \~90% of the nearly half-million annual incident cases of esophageal cancer worldwide. The high costs and invasiveness of upper endoscopy constitute a limitation in providing adequate surveillance for at-risk individuals, including those with previous head and neck cancer. The ANGELA study is a prospective evaluation of the minimally-invasive capsule-sponge device, coupled with tissue biomarkers (p53-immunohistochemistry), to detect squamous neoplasia in high-risk individuals.

NCT Number	NCT06418516
Lead Sponsor	Centre of Postgraduate Medical Education Collaborators: Maria Sklodowska-Curie National Research Institute of Oncology
Conditions	Esophageal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma
Enrollment	340 participants
Start Date	2024-06-01
Primary Completion	2027-02-01 (estimated)
Study Completion	2027-06-01 (estimated)
Updated on ClinicalTrials.gov	2024-05-17